electroCore, Inc. (NASDAQ:ECOR – Get Free Report)’s stock price traded down 0.3% during trading on Monday . The stock traded as low as $6.13 and last traded at $6.44. 47,616 shares changed hands during mid-day trading, an increase of 309% from the average session volume of 11,649 shares. The stock had previously closed at $6.46.
electroCore Stock Down 0.3 %
The stock has a 50-day moving average of $6.05 and a 200 day moving average of $6.24. The stock has a market cap of $38.68 million, a PE ratio of -2.26 and a beta of 0.62.
electroCore (NASDAQ:ECOR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.01. electroCore had a negative net margin of 66.84% and a negative return on equity of 165.17%. The firm had revenue of $6.14 million during the quarter, compared to analyst estimates of $5.85 million. During the same quarter in the prior year, the firm posted ($1.03) earnings per share. Research analysts forecast that electroCore, Inc. will post -1.32 EPS for the current fiscal year.
Insider Activity
Institutional Investors Weigh In On electroCore
An institutional investor recently raised its position in electroCore stock. International Assets Investment Management LLC raised its position in electroCore, Inc. (NASDAQ:ECOR – Free Report) by 49.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,020 shares of the company’s stock after acquiring an additional 17,620 shares during the quarter. International Assets Investment Management LLC owned approximately 0.88% of electroCore worth $324,000 as of its most recent SEC filing. 26.74% of the stock is currently owned by institutional investors.
electroCore Company Profile
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
See Also
- Five stocks we like better than electroCore
- Why Invest in High-Yield Dividend Stocks?
- The Average 401k Balance by Age Explained
- Best Stocks Under $10.00
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Following Congress Stock Trades
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.